Evidence map›Paper›PMID 36385324›Full record

ReviewCurrent cardiology reports2022

Contemporary Data on the Status and Medical Management of Acute Heart Failure.

Maria Anna Bazmpani, Christos A Papanastasiou, Vasileios Kamperidis, Pantelis E Zebekakis, Haralambos Karvounis, Andreas P Kalogeropoulos, Theodoros D Karamitsos

Open access · hybridAbstract readReview
In one paragraph

Review in Current cardiology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 3 pooled it
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 3 syntheses or guidelines pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Observational
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Maria Anna BazmpaniFirst Cardiology Department, Aristotle University of Thessaloniki, AHEPA University Hospital, 1 Stilponos Kyriakides Str, 54636, Thessaloniki, Greece.
Christos A PapanastasiouFirst Cardiology Department, Aristotle University of Thessaloniki, AHEPA University Hospital, 1 Stilponos Kyriakides Str, 54636, Thessaloniki, Greece.
Vasileios KamperidisFirst Cardiology Department, Aristotle University of Thessaloniki, AHEPA University Hospital, 1 Stilponos Kyriakides Str, 54636, Thessaloniki, Greece.
Pantelis E ZebekakisDivision of Nephrology and Hypertension, 1St Department of Medicine, Medical School, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Haralambos KarvounisFirst Cardiology Department, Aristotle University of Thessaloniki, AHEPA University Hospital, 1 Stilponos Kyriakides Str, 54636, Thessaloniki, Greece.
Andreas P KalogeropoulosDivision of Cardiology, Department of Medicine, Stony Brook University, Stony Brook, NY, USA.
Theodoros D KaramitsosFirst Cardiology Department, Aristotle University of Thessaloniki, AHEPA University Hospital, 1 Stilponos Kyriakides Str, 54636, Thessaloniki, Greece. tkaramitsos@auth.gr.ORCID 0000-0002-4658-5273
Aristotle University of Thessaloniki · GRStony Brook University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewAcute heart failure (AHF) is among the leading causes for unplanned hospital admission. Despite advancements in the management of chronic heart failure, the prognosis of AHF remains poor with high in-hospital mortality and increased rates of unfavorable post-discharge outcomes. With this review, we aim to summarize current data on AHF epidemiology, focus on the different patient profiles and classifications, and discuss management, including novel therapeutic options in this area. RECENT

findingsThere is significant heterogeneity among patients admitted for AHF in their baseline characteristics, heart failure (HF) aetiology and precipitating factors leading to decompensation. A novel classification scheme based on four distinct clinical scenarios has been included in the most recent ESC guidelines, in an effort to better risk stratify patients and guide treatment. Intravenous diuretics, vasodilators, and inotropes remain the cornerstone of management in the acute phase, and expansion of use of mechanical circulatory support has been noted in recent years. Meanwhile, many treatments that have proved their value in chronic heart failure demonstrate promising results in the setting of AHF and research in this field is currently ongoing. Acute heart failure remains a major health challenge with high in-hospital mortality and unfavorable post-discharge outcomes. Admission for acute HF represents a window of opportunity for patients to initiate appropriate treatment as soon as possible after stabilization. Future studies are needed to elucidate which patients will benefit the most by available therapies and define the optimal timing for treatment implementation.

Indexed as

AftercareHeart FailureAcute DiseaseDiureticsHumansPatient DischargeDiureticsAcute heart failureEpidemiologyManagementMortality

Identifiers

PMID36385324
PMCPMC9747828
OpenAlexW4309244946

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.